Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Receivables - Other (2020 - 2021)

Historic Receivables - Other for SAB Biotherapeutics (SABS) over the last 2 years, with Q4 2021 value amounting to $6250.0.

  • SAB Biotherapeutics' Receivables - Other changed 0.0% to $6250.0 in Q4 2021 from the same period last year, while for Dec 2021 it was $6250.0, marking a year-over-year change of 0.0%. This contributed to the annual value of $6250.0 for FY2021, which is 0.0% changed from last year.
  • SAB Biotherapeutics' Receivables - Other amounted to $6250.0 in Q4 2021, which was down 0.0% from $6250.0 recorded in Q4 2020.
  • SAB Biotherapeutics' Receivables - Other's 5-year high stood at $6250.0 during Q4 2020, with a 5-year trough of $6250.0 in Q4 2020.